Sienna Gestion Buys 1,976 Shares of Elevance Health, Inc. $ELV

Sienna Gestion boosted its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 11.8% in the fourth quarter, Holdings Channel reports. The firm owned 18,686 shares of the company’s stock after acquiring an additional 1,976 shares during the period. Sienna Gestion’s holdings in Elevance Health were worth $6,485,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the stock. Twin City Private Wealth LLC boosted its position in Elevance Health by 6.5% during the fourth quarter. Twin City Private Wealth LLC now owns 4,767 shares of the company’s stock worth $1,671,000 after purchasing an additional 289 shares during the period. Tamar Securities LLC boosted its position in shares of Elevance Health by 5.3% in the fourth quarter. Tamar Securities LLC now owns 87,406 shares of the company’s stock valued at $30,640,000 after acquiring an additional 4,393 shares during the period. USS Investment Management Ltd boosted its position in shares of Elevance Health by 0.3% in the fourth quarter. USS Investment Management Ltd now owns 36,182 shares of the company’s stock valued at $12,683,000 after acquiring an additional 93 shares during the period. Vanguard Personalized Indexing Management LLC boosted its position in shares of Elevance Health by 2.5% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 30,380 shares of the company’s stock valued at $10,650,000 after acquiring an additional 750 shares during the period. Finally, Mariner LLC boosted its position in shares of Elevance Health by 0.6% in the fourth quarter. Mariner LLC now owns 79,757 shares of the company’s stock valued at $27,955,000 after acquiring an additional 466 shares during the period. Institutional investors own 89.24% of the company’s stock.

Wall Street Analyst Weigh In

ELV has been the subject of several research reports. Weiss Ratings raised Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, May 18th. Robert W. Baird increased their price objective on Elevance Health from $317.00 to $331.00 and gave the company a “neutral” rating in a research report on Thursday, April 23rd. The Goldman Sachs Group increased their price objective on Elevance Health from $350.00 to $370.00 and gave the company a “neutral” rating in a research report on Friday, April 24th. Leerink Partners set a $364.00 price objective on Elevance Health in a research report on Thursday, April 23rd. Finally, Jefferies Financial Group lowered their price target on Elevance Health from $395.00 to $391.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. Fourteen analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Elevance Health presently has an average rating of “Moderate Buy” and a consensus target price of $416.11.

Insider Activity

In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of Elevance Health stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $401.77, for a total transaction of $60,667.27. Following the completion of the transaction, the director directly owned 10,734 shares of the company’s stock, valued at approximately $4,312,599.18. This trade represents a 1.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.34% of the company’s stock.

Elevance Health Stock Down 0.7%

Shares of ELV stock opened at $401.19 on Tuesday. The stock has a market cap of $87.12 billion, a P/E ratio of 17.06, a price-to-earnings-growth ratio of 2.29 and a beta of 0.67. Elevance Health, Inc. has a one year low of $273.71 and a one year high of $426.98. The stock has a fifty day moving average price of $368.63 and a 200 day moving average price of $345.42. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, topping the consensus estimate of $10.74 by $1.84. The firm had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.Elevance Health’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same period last year, the business earned $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Analysts predict that Elevance Health, Inc. will post 26.93 earnings per share for the current year.

Elevance Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be given a $1.72 dividend. This represents a $6.88 annualized dividend and a yield of 1.7%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is 29.26%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.